By Marie Rosenthal, MS
A higher clinical cure rate was found among patients with serious gram-negative bacterial infections who received cefiderocol (Fetroja, Shionogi) as empiric therapy or for a documented infection than among those given it as salvage therapy, according to a presentation at ESCMID Global 2025, in Vienna (poster P2542).
This is the largest real-world study of the effectiveness of the innovative siderophore cephalosporin, also known as Fetcroja outside the United States,